Article

Genetic Testing for GI Cancers: Preventative and Diagnostic

There can be many benefits for patients with gastrointestinal cancers, as well as their loved ones, to undergo genetic testing.

Undergoing genetic testing for gastrointestinal (GI) cancers can be both preventative and diagnostic, explained Matthew Yurgelun, M.D., assistant professor of medicine at the Dana-Farber Cancer Institute.

If someone is already diagnosed with cancer, undergoing genetic and/or molecular testing can offer information about other cancers that they may be at risk for developing, as well as treatment options they may respond best to. For example, patients whose tumors test positive for microsatellite instability-high (MSI-H) status are more likely to have better responses to certain types of immunotherapy.

Genetic counseling can also play a preventative and proactive role for those without cancer, especially for those who have family members with a diagnosis.

Related Videos
Image of man with black hair.
Image of Dr. Fakih.
.Dr. Catherine Wu, chief of the Division of Stem Cell Transplantation and Cellular Therapies at Dana-Farber Cancer Institute, and institute member at the Broad Institute of MIT and Harvard, in Boston
Image of Doctor with blonde hair.
Dr. Katy Beckermann discusses how a Fotivda and Opdivo combination for renal cell carcinoma compared with Fotivda alone based on patient feedback.
Dr. Petros Grivas discusses what precautions should be considered when treating patients with advanced urothelial carcinoma who have diabetes.
Dr. Debu Tripathy discussed the importance of understanding the distinctions between HER2-low and HER2-ultralow breast cancer.
Primary urothelial cancer has variable histologies, making its treatment complex, leading to varied outcomes with high rates of recurrence in patients.
Dr. Neeraj Agarwal is a medical oncologist, a professor of medicine and the Presidential Endowed Chair of Cancer Research at the Huntsman Cancer Institute, University of Utah, as well as director of the Genitourinary Oncology Program and the Center of Investigational Therapeutics at the Huntsman Cancer Institute in Salt Lake City.
Image of Dr. Goy.